Koers ReShape Lifesciences Inc. Other OTC
Aandelen
RSLS
US7611236032
Geavanceerde medische apparatuur & technologie
Omzet 2024 * | 9,99 mln. 9,32 mln. | Omzet 2025 * | 11,99 mln. 11,19 mln. | Marktkapitalisatie | 3,92 mln. 3,65 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -6 mln. -5,6 mln. | Nettowinst (verlies) 2025 * | -5 mln. -4,66 mln. | EV/omzet 2024 * | 0,39 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,33 x |
K/w-verhouding 2024 * |
-0,37
x | K/w-verhouding 2025 * |
-0,46
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,83% |
Recentste transcriptie over ReShape Lifesciences Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Hickey
CEO | Chief Executive Officer | 59 | 01-02-20 |
Director of Finance/CFO | 63 | 15-06-21 | |
Dov Gal
CMP | Compliance Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gary Blackford
BRD | Director/Board Member | 66 | 01-01-16 |
Dan Gladney
CHM | Chairman | 70 | 01-11-15 |
Director/Board Member | 70 | 15-06-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,33% | 219 mld. | |
+6,72% | 183 mld. | |
+10,18% | 132 mld. | |
+24,91% | 106 mld. | |
-0,95% | 62,09 mld. | |
+10,56% | 50,8 mld. | |
+4,81% | 50,88 mld. | |
-0,24% | 40,64 mld. | |
+1,22% | 35,71 mld. |